Introduction to the mechanism of action and latest price trends of Binimetinib

Binimetinib is a selective MEK inhibitor that mainly acts on the MEK1 and MEK2 protein kinases in the MAPK signaling pathway. This pathway is abnormally activated in a variety of tumor types, especially in malignant melanoma, colorectal cancer, and lung cancer with BRAF V600E or NRAS mutations. By inhibiting the activity of MEK, bimetinib can block the proliferation signals of tumor cells, thereby inhibiting the growth and spread of cancer cells. It is often used in combination with BRAF inhibitors (such as encorafenib) and has shown significant efficacy in the treatment of BRAF mutant melanoma.

Although bimetinib has been approved for the treatment of specific BRAF mutation-positive malignant melanoma patients in European and American countries and has been included in standard treatment regimens, it has not yet been officially approved for marketing by the National Food and Drug Administration (NMPA) in mainland China. This means that if mainland patients want to use bimetinib, they still need to rely on overseas drug purchase or obtain it through cross-border medical channels, facing certain drug purchase thresholds and information asymmetry problems.

In terms of price, the Hong Kong original version of bimetinib is currently more common on the market, developed by an American pharmaceutical company. The specification is 15mg*84 tablets. The price of a box is about RMB 1 more than 10,000 yuan. Although this price is slightly lower than in European and American markets, it still poses a certain financial pressure on ordinary patients. In order to reduce the cost of medication, some patients choose to use the generic version of bimetinib produced by the Lao pharmaceutical company Lucius (Lucius). The price is about 6,000 yuan per box. The ingredients and dosage form are basically the same as the original drug. The price advantage is obvious, and it has attracted the attention of patients with limited economic conditions.

However, it should be noted that although generic drugs have the advantage of having consistent ingredients, since they have not been approved by the China Food and Drug Administration, they are still drugs for overseas use. Before use, a doctor should evaluate the risks and efficacy to ensure drug safety. With the gradual advancement of research and development of MEK inhibitors in China, bimetinib or its domestic alternative drugs are expected to be launched in China in the future, further improving drug accessibility and affordability for patients. Prior to this, patients should obtain drugs through formal channels and cooperate with doctors to monitor treatment response to maximize the potential of bimetinib in precision anti-cancer treatment.

Reference materials:https://www.drugs.com/